Well done Stayso-part of the announcement :- Novogen is different. The path we have chosen to take is DIFFERENT BECAUSE current standard and experimental approaches are failing to address the causes of cancer recurrence: the impregnability of the cancer stem cell and the ability of a cancer to survive by continuing to mutate and produce means of beating new therapies.”
Your point of difference is being made.
Ann: Novogen to present at BIO & CEO Investor Conference in NY, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)